Title: Olodaterol: a review of its use in chronic obstructive pulmonary disease.
Journal: Drugs 20150401
Title: Dual regulation of β2-adrenoceptor messenger RNA expression in human lung fibroblasts by β2-cAMP signaling; delayed upregulated inhibitors oppose a rapid in onset, direct stimulation of gene expression.
Journal: Naunyn-Schmiedeberg's archives of pharmacology 20140101
Title: Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.
Journal: International journal of chronic obstructive pulmonary disease 20140101
Title: Olodaterol: first global approval.
Journal: Drugs 20131101
Title: Endothelin-1 enhances β₂-adrenoceptor gene transcription in human lung fibroblasts.
Journal: Life sciences 20121015
Title: β₂-adrenoceptors and muscarinic receptors mediate opposing effects on endothelin-1 expression in human lung fibroblasts.
Journal: European journal of pharmacology 20120915
Title: β₂ long-acting and anticholinergic drugs control TGF-β1-mediated neutrophilic inflammation in COPD.
Journal: Biochimica et biophysica acta 20120701
Title: Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol.
Journal: The Journal of pharmacology and experimental therapeutics 20110601
Title: Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models.
Journal: The Journal of pharmacology and experimental therapeutics 20100701
Title: Discovery of olodaterol, a novel inhaled beta2-adrenoceptor agonist with a 24 h bronchodilatory efficacy.
Journal: Bioorganic & medicinal chemistry letters 20100215
